AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Original Source: FD (FAIR DISCLOSURE) WIRE
OPERATOR: Good day, ladies and gentlemen, and welcome to the Third Quarter 2007 Anadys Pharmaceuticals Incorporated Earnings Conference Call. My name is [Sarah] and I will be your coordinator for today.
I would now like to turn the call over to Ms. Elizabeth Reed, Anadys's Vice President of Legal Affairs and Corporate Secretary. Please proceed.
ELIZABETH REED, VP OF LEGAL AFFAIRS AND CORPORATE SECRETARY, ANADYS PHARMACEUTICALS INC.: Good afternoon and thank you for joining us. On behalf of Anadys Pharmaceuticals, I would like to welcome everyone to our conference call for the third quarter of 2007. I hope you've all had a chance to review today's press release. If you have not and you need a copy, you can visit our website at www.anadyspharma.com.
Before we get started, I would like to call your attention to the Safe Harbor Statement. This conference call and webcast contains certain forward-looking statements within the meaning of the Federal securities laws. These forward-looking statements include, but are not limited to, references to the expected achievement and timing of future milestones for ANA598 and ANA773 and the expected net cash burn for 2007.
Forward-looking statements also include references to the company's timing and plans for initiating clinical investigation of ANA773, the company's beliefs that TLR-7 agonists offer therapeutic potential for cancer, the believed effect of using alternate dosing schedules and the scope and structure of future development activities with ANA773, as well as the company's timing and plans for filing an IND for ANA598 and pending FDA approval, initiating clinical investigation of ANA598, beliefs about the future treatment landscape for HCB, the favorable pharmaceutical properties seen in pre-clinical studies of ANA598 and the belief that these pharmaceutical properties provide the potential for ANA598 to successfully compete as a direct anti-viral in hepatitis-C.
Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ, perhaps materially, from those anticipated or suggested by such forward-looking statements. For example, results of pre-clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that any of its product candidates will not have unforeseen safety issues, will have favorable results in future clinical trials, or will receive regulatory approval.
In addition, Anadys's results may be affected by risks associated with clinical trials and regulatory approval, Anadys's effectiveness at managing its financial resources, the scope and validity of patent protection, as well as competition from other biotechnology and pharmaceutical companies. These and other risk factors are discussed in more detail in our SEC filings, including our Form 10-K for the year ended December 31st, 2006 and our Form 10-Q for the second quarter of 2007.
With that said, I'd like to introduce the members of our management team who will be speaking today. With us, we have Steve Worland, PhD, President and Chief Executive Officer; Jim Glover, Senior Vice President, Operations and Chief Financial Officer; and Jim Freddo, MD, our Chief Medical Officer.
First, Steve Worland will provide a brief introduction. Jim Glover will then summarize our third quarter 2007 financial results. Then Jim Freddo will provide an update on ANA773, and Steve Worland will review the status of ANA598. Following your questions, Steve Worland will then wrap up the call.
At this time, I would like to turn the call over to Steve.
STEVE WORLAND, PRESIDENT AND CEO, ANADYS PHARMACEUTICALS INC.: Thank you, Elizabeth, and thank you to everyone who has joined us on the call today. The third quarter marked an important transition for Anadys. We elected to focus …